| scholarly article | Q13442814 |
| P50 | author | Eric Vallieres | Q58328869 |
| P2093 | author name string | Daniel Y Wu | |
| Rachel S Roberson | |||
| Steven J Kussick | |||
| Szu-Yu J Chen | |||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cellular senescence | Q9075999 |
| P304 | page(s) | 2795-2803 | |
| P577 | publication date | 2005-04-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers | |
| P478 | volume | 65 |
| Q48859144 | 14-3-3β Depletion Drives a Senescence Program in Glioblastoma Cells Through the ERK/SKP2/p27 Pathway. |
| Q48170991 | A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours |
| Q43133466 | A decrease in cyclin B1 levels leads to polyploidization in DNA damage-induced senescence. |
| Q33488475 | A high-throughput method to identify novel senescence-inducing compounds. |
| Q89473494 | A previously identified apoptosis inhibitor iASPP confers resistance to chemotherapeutic drugs by suppressing senescence in cancer cells |
| Q35978702 | Activation of p53 contributes to pseudolaric acid B-induced senescence in human lung cancer cells in vitro |
| Q39239290 | Autophagy, cell death and sustained senescence arrest in B16/F10 melanoma cells and HCT-116 colon carcinoma cells in response to the novel microtubule poison, JG-03-14. |
| Q39875703 | BMP4-Smad signaling pathway mediates adriamycin-induced premature senescence in lung cancer cells |
| Q37705958 | Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD/SCID mice. |
| Q89578028 | Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy |
| Q36960337 | Bmal1 suppresses cancer cell invasion by blocking the phosphoinositide 3-kinase-Akt-MMP-2 signaling pathway |
| Q24299057 | Cancer cell survival following DNA damage-mediated premature senescence is regulated by mammalian target of rapamycin (mTOR)-dependent Inhibition of sirtuin 1 |
| Q40859595 | Cancer-associated S100P protein binds and inactivates p53, permits therapy-induced senescence and supports chemoresistance |
| Q42571312 | Carnitine-induced senescence in glioblastoma cells |
| Q35947022 | Cellular senescence and cancer chemotherapy resistance |
| Q35815320 | Cellular senescence and organismal aging |
| Q42426506 | Cellular senescence predicts treatment outcome in metastasised colorectal cancer. |
| Q29615561 | Cellular senescence: when bad things happen to good cells |
| Q41907815 | Characterization of Senescence of Culture-expanded Human Adipose-derived Mesenchymal Stem Cells |
| Q38794974 | Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy |
| Q96607407 | Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives |
| Q38248932 | DNA double strand break responses and chromatin alterations within the aging cell |
| Q36199857 | Decreased skp2 expression is necessary but not sufficient for therapy-induced senescence in prostate cancer |
| Q52935837 | Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. |
| Q36608493 | Drug-induced senescence bystander proliferation in prostate cancer cells in vitro and in vivo |
| Q38609721 | EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks |
| Q34782417 | EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation |
| Q36210992 | Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial |
| Q39135563 | Enhanced killing of therapy-induced senescent tumor cells by oncolytic measles vaccine viruses |
| Q33733121 | Escape of U251 glioma cells from temozolomide-induced senescence was modulated by CDK1/survivin signaling |
| Q36222142 | Evaluation of the compact high-field orbitrap for top-down proteomics of human cells |
| Q30498068 | Expression of coxsackie and adenovirus receptor distinguishes transitional cancer states in therapy-induced cellular senescence |
| Q36224261 | Expression of p14(ARF), p15(INK4b), p16(INK4a) and skp2 increases during esophageal squamous cell cancer progression |
| Q34252309 | Extensive Disease Small Cell Lung Cancer Dose-Response Relationships: Implications for Resistance Mechanisms |
| Q39777394 | Features of senescence and cell death induced by doxorubicin in A549 cells: organization and level of selected cytoskeletal proteins. |
| Q36916118 | Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines. |
| Q64243102 | HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells |
| Q37785490 | Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes |
| Q58699475 | ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib |
| Q39198938 | IL1- and TGFβ-Nox4 signaling, oxidative stress and DNA damage response are shared features of replicative, oncogene-induced, and drug-induced paracrine 'bystander senescence'. |
| Q90857560 | Identification and characterization of Cardiac Glycosides as senolytic compounds |
| Q30585968 | Immortalised breast epithelia survive prolonged DNA replication stress and return to cycle from a senescent-like state. |
| Q52331716 | Inducers of Senescence, Toxic Compounds, and Senolytics: The Multiple Faces of Nrf2-Activating Phytochemicals in Cancer Adjuvant Therapy. |
| Q38696611 | Induction of accelerated senescence by the microtubule-stabilizing agent peloruside A. |
| Q61806041 | Inhibition of FAK Signaling Elicits Lamin A/C-Associated Nuclear Deformity and Cellular Senescence |
| Q50643738 | Inhibition of Twist1-mediated invasion by Chk2 promotes premature senescence in p53-defective cancer cells. |
| Q35640152 | Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence |
| Q37295309 | Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development |
| Q33577558 | Involvement of autophagy induction in penta-1,2,3,4,6-O-galloyl-β-D-glucose-induced senescence-like growth arrest in human cancer cells |
| Q38578526 | Is reliance on mitochondrial respiration a "chink in the armor" of therapy-resistant cancer? |
| Q38286386 | Key points of basic theories and clinical practice in rAd-p53 ( Gendicine ™) gene therapy for solid malignant tumors |
| Q36689527 | Low-dose etoposide-treatment induces endoreplication and cell death accompanied by cytoskeletal alterations in A549 cells: Does the response involve senescence? The possible role of vimentin |
| Q28251805 | Mapping intact protein isoforms in discovery mode using top-down proteomics |
| Q58799971 | Matrine induces senescence of human glioblastoma cells through suppression of the IGF1/PI3K/AKT/p27 signaling pathway |
| Q92629967 | Mechanisms and significance of therapy-induced and spontaneous senescence of cancer cells |
| Q36661775 | Mutant p53 proteins: between loss and gain of function |
| Q39181854 | Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells |
| Q92442206 | Network Pharmacology Approach Reveals the Potential Immune Function Activation and Tumor Cell Apoptosis Promotion of Xia Qi Decoction in Lung Cancer |
| Q45070329 | Nicotine prevents and reverses paclitaxel-induced mechanical allodynia in a mouse model of CIPN. |
| Q55312849 | Non-Cell Autonomous Effects of the Senescence-Associated Secretory Phenotype in Cancer Therapy. |
| Q36781105 | Nucleolar repression facilitates initiation and maintenance of senescence |
| Q37890974 | Oncogene-induced senescence and its role in tumor suppression. |
| Q37784324 | Oncogene-induced senescence: the bright and dark side of the response |
| Q60935673 | Oncogenic Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and Cancer Stem Cell Phenotype |
| Q39889891 | Oxidative Stress Increases the Number of Stress Granules in Senescent Cells and Triggers a Rapid Decrease in p21waf1/cip1 Translation |
| Q40284724 | Oxidative stress induces a prolonged but reversible arrest in p53-null cancer cells, involving a Chk1-dependent G2 checkpoint. |
| Q38981503 | PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma |
| Q47437818 | PRMT5 as a druggable target for glioblastoma therapy. |
| Q88402407 | Paracrine roles of cellular senescence in promoting tumourigenesis |
| Q39300990 | Persistent DNA damage caused by low levels of mitomycin C induces irreversible cell senescence |
| Q39605271 | Polyploid tumour cells elicit paradiploid progeny through depolyploidizing divisions and regulated autophagic degradation |
| Q54486386 | Polyploidy road to therapy-induced cellular senescence and escape. |
| Q42123911 | Primary and compensatory roles for RB family members at cell cycle gene promoters that are deacetylated and downregulated in doxorubicin-induced senescence of breast cancer cells |
| Q37893959 | Pro-senescence therapy for cancer treatment |
| Q37053539 | Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis |
| Q36337922 | Prospects of RNA interference therapy for cancer |
| Q35118638 | Proteomics analysis of normal and senescent NG108-15 cells: GRP78 plays a negative role in cisplatin-induced senescence in the NG108-15 cell line |
| Q26744325 | ROS, Cell Senescence, and Novel Molecular Mechanisms in Aging and Age-Related Diseases |
| Q34116777 | Radiation-induced cell death mechanisms |
| Q36767034 | Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells |
| Q91643126 | Radiosensitization of Non-Small Cell Lung Cancer Cells by the Plk1 Inhibitor Volasertib Is Dependent on the p53 Status |
| Q39002281 | Reactive oxygen species generation is essential for cisplatin-induced accelerated senescence in hepatocellular carcinoma |
| Q22252669 | Relationships between cancer and aging: a multilevel approach |
| Q36725453 | Repopulation of ovarian cancer cells after chemotherapy |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q60045574 | Reversible senescence of human colon cancer cells after blockage of mitosis/cytokinesis caused by the CNF1 cyclomodulin from Escherichia coli |
| Q36780731 | Role of stress-activated OCT4A in the cell fate decisions of embryonal carcinoma cells treated with etoposide. |
| Q39456823 | SASP: Tumor Suppressor or Promoter? Yes! |
| Q93116127 | SETD1A protects from senescence through regulation of the mitotic gene expression program |
| Q33710045 | Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival [...] |
| Q96431462 | Senescence as a therapeutically relevant response to CDK4/6 inhibitors |
| Q36903843 | Senescence in tumours: evidence from mice and humans |
| Q96122993 | Senescent Cells in Cancer Therapy: Friends or Foes? |
| Q33702243 | Senescent tumor cells lead the collective invasion in thyroid cancer |
| Q93060574 | Short and Long-Term Effects of the Exposure of Breast Cancer Cell Lines to Different Ratios of Free or Co-Encapsulated Liposomal Paclitaxel and Doxorubicin |
| Q51766043 | Simultaneous induction and blockade of autophagy by a single agent. |
| Q38218129 | Size Does Matter: Why Polyploid Tumor Cells are Critical Drug Targets in the War on Cancer. |
| Q28068732 | Small molecule compounds that induce cellular senescence |
| Q47624450 | Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. |
| Q92242813 | Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy Resistance |
| Q27497212 | Stem cells, senescence, neosis and self-renewal in cancer |
| Q34350843 | Suppressed expression of T-box transcription factors is involved in senescence in chronic obstructive pulmonary disease |
| Q34400375 | Survivin and escaping in therapy-induced cellular senescence |
| Q93350345 | Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells |
| Q39776763 | The ATM and ATR inhibitors CGK733 and caffeine suppress cyclin D1 levels and inhibit cell proliferation |
| Q38984960 | The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells |
| Q26825221 | The impact of cellular senescence in cancer therapy: is it true or not? |
| Q53345760 | The power and the promise of oncogene-induced senescence markers. |
| Q30426400 | The yin-yang of DNA damage response: roles in tumorigenesis and cellular senescence |
| Q27027457 | Therapeutic targeting of replicative immortality |
| Q34212773 | Therapy-Induced Senescence in Cancer |
| Q33590178 | Three steps to the immortality of cancer cells: senescence, polyploidy and self-renewal |
| Q54962871 | Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB. |
| Q35740145 | Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy |
| Q28396304 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer |
| Q41464237 | Tumor cell senescence response produces aggressive variants. |
| Q57271780 | Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells |
| Q35585808 | What has senescence got to do with cancer? |
| Q36021953 | Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer |
| Q33825111 | p35 is required for CDK5 activation in cellular senescence |
| Q88934867 | p53 Mediates Vast Gene Expression Changes That Contribute to Poor Chemotherapeutic Response in a Mouse Model of Breast Cancer |
Search more.